Global Life Science Market is valued at USD 162.4 Billion in 2024 and expected to reach USD 234.3 Billion by 2030 with a CAGR of 6.3% over the forecast period.
Life science products refer to a diverse range of tools, equipment, consumables, reagents, and technologies used in scientific research, diagnostics, and industrial applications in the fields of biology, biotechnology, genetics, and other life sciences. Life science products play a pivotal role in various industries, including pharmaceuticals, healthcare, agriculture, and environmental science.
Life science goods have developed from simple laboratory instruments to extremely sophisticated technologies, and they now serve a crucial role in scientific research, healthcare, biotechnology, and many other disciplines. Their current importance may be seen in their widespread application, which has advanced our knowledge of how life works and improved human health and well-being. It is a hub of innovation, where cutting-edge technologies, methodologies, and products are continuously developed to support scientific exploration. This market is at the forefront of pioneering research in genomics, proteomics, molecular biology, and other critical areas.
The end users of life science products include Pharmaceutical Companies, Biotechnology Companies, Academic and Research Institutions, Hospitals and Clinical Laboratories, Food and Beverage Industry, Government and Regulatory Agencies, and Contract Research Organizations.
The revenue generation in the global life science product market is driven by a combination of product sales, innovation, diversification, global expansion, strategic pricing, and value-added services. They mostly follow B2B distribution channels, subscription-based services, service contracts for maintenance and support of analytical instruments, and research and development collaborations. For instance, Thermo Fisher Scientific generates significant revenue through the sale of laboratory equipment, reagents, and consumables to research institutions, pharmaceutical companies, and diagnostic laboratories worldwide. Laboratories frequently employ their high-performance liquid chromatography (HPLC) equipment for analytical and preparative purposes. Also, Qiagen reported partnering with Neuron23 to develop a next-generation sequencing companion diagnostic for novel Parkinson’s disease drugs.
A supply chain analysis for the global life science products market involves examining the complex network of activities and processes that contribute to the production, distribution, and delivery of life science products to end-users. This analysis helps stakeholders in the industry understand the efficiency, cost-effectiveness, and potential vulnerabilities of the supply chain. Several companies in the life science product industry have embraced innovations and trends to enhance their operations and offerings. AI and blockchain technology helped to enhance the operations and offerings. Illumina Inc. (a global leader in DNA sequencing and array-based technologies) is a pioneer in the field of genomics and DNA sequencing. Illumina Inc. developed the NovaSeq platform, a high-throughput DNA sequencer that significantly reduces the cost of sequencing and accelerates genomic research. They also actively invest in AI and data analytics to extract meaningful insights from genetic data.
The value chain model in the global life science product market may prove to be a costly affair since the development of innovative products and technologies in the life science products market often requires substantial R&D investments. Costs associated with quality control, validation, and adherence to Good Manufacturing Practices (GMP) are incurred in order to comply with strict regulatory standards in the life sciences sector. Companies like Thermo Fisher Scientific optimize their supply chain operations to reduce costs and ensure timely delivery of products to customers worldwide. Leveraging digital technologies like data analytics and IoT for better supply chain visibility and decision-making. Organizations can spend money on energy-efficient manufacturing, eco-friendly packaging, and sustainable material procurement.
The COVID-19 pandemic magnified the importance of digital advances as companies raced to meet the demand for new testing, vaccines, and treatments to combat the pandemic. Demand surged for diagnostic kits, research reagents, and medical equipment, creating opportunities for companies in these segments. However, disruptions in supply chains, logistical challenges, and the redirection of resources to pandemic-related efforts also posed hurdles. The pandemic accelerated digitalization, emphasizing the importance of technologies like telemedicine and data analytics. Life science products played a pivotal role in the fight against COVID-19, contributing to diagnostics, vaccine development, treatment, and research efforts. Thousands of SARS-CoV-2 genomes were sequenced worldwide, aiding in surveillance efforts and vaccine adaptation. Companies like Pfizer and Moderna utilized life science products, such as bioreactors and purification systems, in the development and production of mRNA vaccines. Thousands of SARS-CoV-2 genomes were sequenced worldwide, aiding in surveillance efforts and vaccine adaptation.
Some major key players for the global life science product market report cover prominent players like Merck Millipore Limited, PerkinElmer, Sigma Aldrich Corp, Abcam, A.M.S. Biotechnology (Europe), Johnson & Johnson (J&J), Bio-Rad Laboratories, BPS Bioscience, Crown Bioscience, Genscript Biotech Corporation, Thermo Fisher Scientific, Agilent Technologies, Becton, Dickinson and Company, Qiagen, Bio-Rad Laboratories, Inc, Agios Pharmaceuticals, Illumina, Inc, Zeiss International, Oxford Instruments plc.
Chronic diseases are long-term health conditions that often require ongoing medical management and treatment. Examples include diabetes, cardiovascular diseases (such as hypertension and heart disease), cancer, chronic respiratory diseases, and neurodegenerative diseases. For instance, about 21% of the elderly in India reportedly have at least one chronic disease. Also, according to the national Library of Medicine, Between 2020 and 2050, there will be a 61.1% increase in the number of Americans aged 50 and older, from 137.25 million to 221.1 million. There will be 142.66 million people aged 50 and older in 2050 who have at least one chronic disease, up from 71.522 million in 2020, a 99.5% rise. Simultaneously, it is anticipated that the number of people with multimorbidity will rise by 91.16%, from 7.8304 million in 2020 to 14.968 million in 2050. The prevalence of chronic diseases like diabetes and cardiovascular conditions has led to a growing demand for diagnostic tests, treatments, and monitoring devices.
The rise in chronic diseases fuels research and development efforts to discover and develop new therapeutic agents and treatments. Hence, Biotechnology advancements continue to push the boundaries of scientific knowledge and innovation. For instance, The development of gene therapies for rare diseases and cancer treatment has expanded the market for specialized life science products. Also, investments in pandemic preparedness increased as a result of the pandemic, which highlighted the value of diagnostics, vaccines, and treatments. In the U.K., in order to support the implementation of the Science and Technology framework, the UK Chancellor has announced a US$ 696.1 million life sciences growth package. This funding will be used to change regulations, increase investment, and develop talent and skills. In addition, US$ 10.7 million will go to support UK organizations and researchers to create novel pharmaceuticals, MedTech, and digital tools.
Rapid diagnostic tests and vaccine development for COVID-19 have been a focal point, with many companies and research institutions contributing to the global responses. Billions of COVID-19 tests have been conducted globally, and multiple vaccines have been developed and distributed in record time.
Life science products often involve cutting-edge science, requiring extensive research into the underlying biological, chemical, or genetic mechanisms. Years of study are required to identify the appropriate molecular target and create a medicine that successfully modulates it in order to develop a novel treatment for a complicated disease like cancer. A Phase III clinical trial for a new drug may involve thousands of patients, with costs running into millions or even billions of dollars. Pfizer-BioNTech invested approximately US$2 billion in research and development for its COVID-19 vaccine, according to their financial reports.
The high R&D costs in the life science products market are a reflection of the industry's commitment to innovation, quality, and safety. While these costs are substantial, they are necessary to advance medical science, develop new therapies, and improve healthcare outcomes.
Regulatory frameworks are complex and continually evolving, requiring companies to stay updated on changes in rules and guidelines. Companies must invest substantial resources in extensive testing, documentation, and compliance efforts to meet these stringent standards since regulatory agencies, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others, impose strict requirements on the safety, efficacy, and quality of life science products.
The European Union's Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) introduced more rigorous requirements for medical devices and diagnostics, impacting product approval timelines and costs. According to a report by MedTech Europe, the implementation of MDR was expected to result in a significant increase in costs and potential delays in bringing new medical devices to market.
Opportunities in the life science products market include the development of new technologies that improve accuracy and efficiency, growing demand for healthcare services and products, and population aging.
For example, according to the World Health Organization Report, at the biological level, aging results from the impact of the accumulation of a wide variety of molecular and cellular damage over time. Asian biotech firms are investing in research to develop novel therapies that could prevent and reverse the aging process in humans. This leads to a gradual decrease in physical and mental capacity, a growing risk of disease, and ultimately death. To cater to the need for healthcare solutions Life science companies can develop and offer products targeted at addressing age-related health challenges, including diagnostics, pharmaceuticals, and medical devices.
Market trends in the global life science products market reflect the industry's ongoing evolution, driven by technological advancements, regulatory changes, and shifts in healthcare and research priorities the increasing use of automation and artificial intelligence in data analysis.
Versatile and efficient AI: The most popular technologies now used in drug research and development across the globe are AI and big data, and this trend is predicted to continue in the APAC region over time. In a wide range of applications, including genetic risk assessment, early and precise illness screening and diagnosis, drug discovery and development, clinical trial design and analysis, precision medicine, and treatment response monitoring, AI is flexible and effective. Therefore, pharmaceutical companies will continue to invest in this technology.
Advancements in Genomic Sequencing: The incorporation of gene technology and genetic information in treatments is projected to soar. This is particularly important in the field of oncology as 1 in 6 global deaths is caused by cancer. Continued advancements in genomic sequencing technologies were driving research and diagnostics in areas such as precision medicine and genomics. It has already been a record year for the approval of new gene therapies to treat rare diseases, as the United States Food and Drug Administration (USFDA) approved the first hemophilia B gene therapy. At present 16 therapies are on track for regulatory decisions in 2023 indicating an active late-stage pipeline.
In North America, the market for life science products is driven by factors such as partnerships, increased healthcare spending, and technological innovation.
For example- according to a report established on May 30, 2023. ValGenesis and Life Science Consulting Pvt. Ltd. Form a Partnership to Enhance Quality and Compliance for Life Sciences disciplines such as production, quality control and assurance, information technology, and research and development (R&D). Moreover, biotechnology companies in North America, including Moderna and Pfizer, have made extensive use of technology in the research and development of mRNA vaccines for COVID-19. These vaccines are based on advanced biotechnology and genomic sequencing techniques that allow for the rapid development of vaccines tailored to specific viral strains.
The Asia Pacific life science products market is a significant and growing market, driven by a number of factors such as the increasing chronic diseases and aging population and the increasing demand for more advanced and efficient diagnostic tools. According to the World Health Organization Report published on 1st October 2022, between 2015 and 2050, the proportion of the world's population over 60 years will nearly double from 12% to 22%. In Japan, 30% of the population is already over 60 years old and by 2050, two-thirds of the world’s population over 60 years will live in low- and middle-income countries. This states that soon life science products industry will expand rapidly. Also, during the global pandemic APAC countries, including China and India, played significant roles in vaccine development and production. The demand for diagnostic products, including PCR tests, reagents, and testing equipment, skyrocketed as countries across APAC ramped up testing efforts to detect and control the spread of the virus.
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us email@example.comJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®